



Social Media Toolkit

2024 U.S. Generic & Biosimilar Medicines Savings Report

Generic and biosimilar medicines saved America's patients and the U.S. healthcare system \$445 billion in 2023. But the continued savings achieved through use of lower-cost generics and biosimilars can no longer be taken for granted. The long-term outlook for generic and biosimilar competition hinges on addressing the barriers to development and adoption and, ultimately, sustainability of this vital industry. Without action to strengthen the generic and biosimilars markets, many of these lower-cost medicines may disappear. And patients' access to care will suffer. By utilizing this social media toolkit, you can keep to ensure more patients have more access to lifesaving medicines!

#GRxBiosimsSavingsReport

The 2024 Savings Report

- AAM Website: accessiblemeds.org
- AAM Report Page: accessiblemeds.org/resources/blog/2024-savings-report
- Biosimilars Council Website: biosimilarscouncil.org
- Biosimilars Council Report Page: biosimilarscouncil.org/resource/2024-US-generic-biosimilar-savings-report

Follow AAM



Follow Biosimilars Council



Help Spread the Word

We encourage you to utilize the info in this toolkit to help raise awareness around the benefit of generic and biosimilar medicines—as well as the impact policy and regulatory decisions can have on the sustainability of this essential industry. Please post on any or all of your favorite social media channels and please include the hashtag [#GRxBiosimsSavingsReport](#). Please also consider tagging [@accessiblemeds](#) and [@biosimscouncil](#) – so we can share your message on our channels, too!

Social-Ready Graphics

Download all images [here](#) 

Hashtags

[#GRxBiosimsSavingsReport](#)



[#Generics](#)

[#GenericDrugs](#)

[#GenericMedicines](#)



[#Biosimilars](#)

Questions? Please email the AAM Communications Department at: media@accessiblemeds.org




#Generics & #biosimilars saved \$445 billion in 2023. But strong and swift legislative and regulatory action to safeguard this essential industry is vital to continue providing lifesaving and life-changing medications to patients at prices they can afford. Learn more in the #GRxBiosimsSavingsReport: <https://accessiblemeds.org/resources/blog/2024-savings-report>

As we mark the 40th Anniversary of the Hatch-Waxman Act on September 24th, we stand at a critical crossroads. Will lawmakers enact policies that support a healthy market – one that saved the U.S. healthcare system \$3.1 trillion in the past 10 years? Or will lawmakers enable anti-competitive behaviors that suppress patient-access to the medicines? More on this critical juncture: <https://accessiblemeds.org/resources/blog/2024-savings-report> #GRxBiosimsSavingsReport



In 2023, #generics & #biosimilars saved America’s patients and the U.S. healthcare system \$445 billion. Learn more—including what can be done to help safeguard this important industry: <https://accessiblemeds.org/resources/blog/2024-savings-report> #GRxBiosimsSavingsReport

In 2023, #generics & #biosimilars represented a whopping 90% of all prescriptions filled and only 13% of all drug spending in the U.S. In fact, generic & biosimilar medicines are the only aspect of healthcare that CONSISTENTLY deliver lower costs for patients! Learn more in AAM’s 2024 Savings Report: <https://accessiblemeds.org/resources/blog/2024-savings-report> #GRxBiosimsSavingsReport




Did you know: Although patients are prescribed a **#generic** or **#biosimilar** 90% of the time, they accounted for only 1.2% of total U.S. healthcare spending in 2023? Learn more: <https://accessiblemeds.org/resources/blog/2024-savings-report> **#GRxBiosimsSavingsReport**

Generics And Biosimilars Save Billions for Patients
Generic and Biosimilar Medicines Provide Significant Relief for Patients With Chronic and Acute Conditions Alike


Savings by Condition	
Products	Total Savings (Primary Condition + Comorbidities)
Heart Disease	\$118.1 billion
Mental Illness	\$76.4 billion
Diabetes	\$61 billion
Cancers	\$25.5 billion
Allergies & Asthma	\$13 billion
Arthritis	\$5.6 billion
Multiple Sclerosis	\$4.6 billion
Crohn's & Colitis	\$2.4 billion
Bone Disease (Osteoporosis, Osteoarthritis, etc.)	\$2.2 billion
Autoimmune Diseases	\$350 million

Source: IQVIA National Prescription Audit, December 2023.



#Generic & #biosimilar medicines save BILLIONS for U.S. patients. To better understand the value of these essential and affordable drugs, take a look at the savings specific to some common patient conditions and learn more, here: <https://accessiblemeds.org/resources/blog/2024-savings-report> **#GRxBiosimsSavingsReport**



Decisions by PBMs and health plans to shift **#generics** to non-generic tiers increases copays and imposes higher costs on patients. THE BOTTOM LINE: U.S. patients are overpaying for medicines because of PBMs. Learn the facts: <https://accessiblemeds.org/resources/blog/2024-savings-report> **#GRxBiosimsSavingsReport**



DRUG SHORTAGES HAMPER PATIENT CARE! The increase in **#generic** shortages is a result of unsustainably low pricing, increases in government policies that further compound market dynamics, and regulatory challenges. Learn more in the 2024 **#GRxBiosimsSavingsReport**: <https://accessiblemeds.org/resources/blog/2024-savings-report>



Since the first #biosimilar launch in 2015, patients and the healthcare system have saved \$36 billion. Although savings have grown, biosimilar adoption remains too low! Learn about how PBM formulary practices favoring high-priced brand biologics with high rebates (\$ going back to PBMs) undermine biosimilar adoption: <https://accessiblemeds.org/resources/blog/2024-savings-report> #GRxBiosimsSavingsReport

Since 2015, #biosimilars have been used in 2.7 billion days of patient therapy with no meaningful differences in safety or clinical outcomes, and biosimilars have allowed 495 million days of additional patient therapy. #Biosimilar medicines are safe and effective and saved patients and the U.S. healthcare system \$12.4 billion in 2023. Learn more: <https://accessiblemeds.org/resources/blog/2024-savings-report> #GRxBiosimsSavingsReport